The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke – Pilot study

Biomedical Papers

Volumn 160, Issue 4, 2016, Pages 543-548

  Dluha, Jana ^a   Sivak, Stefan ^a   Kurca, Egon ^a   Dusenka, Robert ^a   Kalmarova, Klaudia ^a   Koprusakova, Monika Turcanova ^a   Kantorova, Ema ^a   Nosal, Vladimir ^a  

^a Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

Acute ischemic stroke; Efficacy; Heparin; mRS; Nadroparin; Safety

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

AGED; BLEEDING; BRAIN ISCHEMIA; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS DRUG ADMINISTRATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NADROPARIN; PILOT PROJECTS; PROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 85006280090     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2016.042     Document Type: Article

References (23)

1. Bonita R, Stewart A, Beaglehole R. International trends in stroke mortality: 1970-1985. Stroke 1990;21:989-92.
2. Feigin VL, Lawes CMM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case fatality in the late 20th century. Lancet Neurol 2003;2(1):43-53.
3. Hankey GJ, Warlow C. Treatment and second prevention of stroke: evidence, costs and effects on individuals and populations. Lancet 1999;354(9188):1457-63.
4. Rödén-Jüllig A, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Intern Med 2000;248(4):287-91.
5. Bejot Y, Rouaud O, Durier J. Decrease in the stroke case fatality rates in a French population-based twenty-year study. Cerebrovasc Dis 2007;24:439-44.
6. Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7.
7. Hacke W, Kaste M, Bluhmki E. Thrombolysis Alteplase 3 to 4,5 Hours after Acute Ischemic Stroke. N Eng J Med 2008;359(13):1317-29.
8. Berkhemer OA, Fransen PS, Beumer D. A randomized trial of intraarterial treatment for acute ischemic stroke. New England Journal of Medicine 2015;372:11-20.
9. Campbell BCV, Mitchell PT, Kleining TJ. Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. N Engl J Med 2015;372(11)-1009-18.
10. Goyal M, Demchuk AM, Menon BK. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372(11):1019-30.
11. Marsh EE, Adams HP, Biller J, Wasek P, Banwart K, Mitchell V, Woolson R. (1989). Use of antithrombotic drugs in the treatment of acute ischemic stroke A survey of neurologists in practice in the United States. Neurology 1989;39(12):1631-4.
12. Bath P, Leonardi-Bee J, Bath F. Low molecular weight heparin versus aspirin for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2002;11(2):55-62.
13. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecularweight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study: HAEST Study Group: Heparin in Acute Embolic Stroke Trial. Lancet 2000;355(9211):1205-10.
14. Camerlingo M, Salvi P, Belloni G. Intravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infrartions. Stroke 2005;36(11):2415-20.
15. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569-81.
16. Kay R, Wong KS, Yu YL. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333(24):1588-94.
17. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007;38(2):423-30.
18. Rothwell PM, Coull AJ, Giles MF. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363(9425):1925-33.
19. Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischeaemic stroke. Cochrane Database Syst Rev 2008;(4):CD000024.
20. European Stroke Organisation (ESO) Executive Committee, and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25(5):457-507.
21. Jauch EC, Saver JL, Adams HP. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44(3):870-947.
22. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial. JAMA 1998;279(16):1265-72.
23. Wang Q, Chen C, Chen XY. Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease. Arch Neurol 2012; 69(11):1454-60.